Fig. 3From: Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experiencea: Patient case. Of note, a depicts a patient with liver dominant metastatic uveal melanoma at baseline before first chemosaturation with percutaneous hepatic perfusion (CS-PHP) treatment. The patient responded with partial remission 3 month after first CS-PHP procedure (b). Sustained hepatic tumor control was achieved for 30 months by five treatments with CS-PHP, while extrahepatic progressive disease was noted (c). After a sixth CS-PHP application and 35 months after first CS-PHP therapy, progression was diagnosed intra- and extrahepatically (d). b: Patient case. Of note, (a) T2 weighted images of a patient with liver dominant metastatic uveal melanoma at baseline before first chemosaturation with percutaneous hepatic perfusion (CS-PHP) treatment. The patient responded with partial remission 3 month after first CS-PHP procedure (b). Sustained hepatic tumor control was achieved for 13 months (c). Progression was diagnosed intrahepatically after 17 months, and patient was scheduled for a new CS-PHP (d)Back to article page